



## Health Plus Partnership Program

The following list of drugs prescribed in Hong Kong to the insured members under AIA designated group policies are eligible under the Health Plus Partnership Program ('the Program'), subject to the relevant terms and conditions.

<b>Name of Drugs</b>	<b>Effective Date of Drug's Eligibility under the Program</b>
Faslodex (Fulvestrant)	3 May 2022
Kisqali (Ribociclib)*	3 May 2022 until 31 October 2024
Piqray (Alpelisib)*	3 May 2022 until 31 October 2024
Talzenna (Talazoparib)	3 May 2022
Verzenio (Abemaciclib)	3 May 2022
Zoladex (Goserelin)	3 May 2022

\*Please be informed on 30 August 2024 that the above drugs from Novartis, Kisqali (Ribociclib) and Piqray (Alpelisib), will be ceased to be eligible under the Program with effect from 1 November 2024.

### Remarks:

- This material is for use of the Program only and applicable to AIA designated group insurance policies. All group insurance policies are subject to terms and conditions, exclusions and limitations, please refer to relevant policy contract for detail.
- Claim procedures: Insured MUST submit the Group Insurance Medical Claim Form or Group Medical Insurance - Hospitalisation & Surgical Claim Form in paper with the original receipt(s) / supporting documents to AIA within 90 days from the date of drug prescription. The original receipt(s) / supporting documents must contain information including the drug name(s), cost of each drug, date of prescription, patient's name, and must be supported by the attending physician's prescription and / or recommendation and / or the original receipt(s) from the pharmacy. For details, please refer to the relevant member leaflet.
- AIA and its intermediaries do not have relevant licenses and/or qualifications to provide medical services or advice and is not the provider of the drugs.
- AIA does not recommend nor promote any drugs and will not take any liabilities nor responsibilities for any medical incidents and medication decisions made by the doctor. Insured members shall seek professional medical advice (including that for prescription) from the registered doctors.
- AIA reserves the right to make any changes on the information in this webpage from time to time.

Date of this webpage last updated: 30 August 2024



## 攜手增益藥物計劃

下列於香港處方的藥物名單適用於指定 AIA 團體保單的攜手增益藥物計劃（下稱「藥物計劃」），並受相關條款及細則約束。

藥物名稱	在藥物計劃下的生效日期
Faslodex (Fulvestrant)	2022 年 5 月 3 日
Kisqali (Ribociclib)*	2022 年 5 月 3 日至 2024 年 10 月 31 日
Piqray (Alpelisib)*	2022 年 5 月 3 日至 2024 年 10 月 31 日
Talzenna (Talazoparib)	2022 年 5 月 3 日
Verzenio (Abemaciclib)	2022 年 5 月 3 日
Zoladex (Goserelin)	2022 年 5 月 3 日

\*於 2024 年 8 月 30 日謹此通知上述諾華之藥物 Kisqali (Ribociclib) 和 Piqray (Alpelisib)將於 2024 年 11 月 1 日停止適用於藥物計劃下。

### 備註：

- 此文件只適用於藥物計劃及指定 AIA 團體醫療保險計劃。所有團體醫療保險計劃受限於條款及細則、不保事項、產品限制，有關詳情，請參閱相關產品之保單契約。
- 索償手續：受保人必須提交紙本「團體醫療保險賠償申請表」或「團體醫療保險－住院及手術賠償申請表」，並連同收據正本/ 相關文件，於藥物處方日起九十日內一併遞交。收據正本/ 相關文件必須包括藥物名稱、每一藥物費用、處方日期、病者姓名，以及必須有主診醫生處方及/ 或認可及/ 或藥房之收據正本。詳情請參閱有關成員單張。
- AIA 及其中介人並無可以提供醫療服務或建議的相關牌照及/或資格，亦非相關藥物的提供者。
- AIA 不會提供或推廣任何藥物，及不會對醫生做出的任何醫療事故和利用藥決定承擔任何責任或義務。就任何專業醫療建議(包括處方藥物)，受保成員應諮詢其註冊醫生。
- AIA 保留不時更改本網頁所載資料的權利。

本網頁的最後更新日期: 2024 年 8 月 30 日